Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Stevens

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
British Journal of Clinical Pharmacology|August 19, 2010
Pharmacoeconomics: NICE's approach to decision-makingMichael Rawlins, David Barnett, Andrew Stevens
International Journal of Technology Assessment in Health Care|September 21, 2006
International diffusion of new health technologies: a ten-country analysis of six health technologiesClaire Packer, Sue Simpson, Andrew Stevens, et al.
International Journal of Technology Assessment in Health Care|September 18, 2012
Analyzing 10 years of early awareness and alert activity in the United kingdomClaire Packer, Matthew Fung, Andrew Stevens
Radiology Case Reports|April 25, 2022
Fatal intracranial hemorrhage as the presenting sign of acute promyelocytic leukemia: A case reportEleanor C Smith, E Andrew Stevens
The Lancet. Oncology|January 1, 2009
Erlotinib for the treatment of non-small-cell lung cancerMeindert Boysen, Carole Longson, Andrew Stevens
BMJ Open|May 8, 2019
Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areasDerek J Ward, Lucy Doos, Andrew Stevens
Journal of Medical Ethics|January 4, 2012
National Institute for Health and Clinical Excellence appraisal and ageismAndrew Stevens, Nick Doyle, Peter Littlejohns, et al.
International Journal of Technology Assessment in Health Care|November 3, 2005
Predicting the impact of new health technologies on average length of stay: development of a prediction frameworkSue Simpson, Claire Packer, Andrew Stevens, et al.
The Lancet. Oncology|April 15, 2008
Rituximab for follicular non-Hodgkin lymphomaElangovan Gajraj, Helen Chung, Carole Longson, et al.
BMJ (Clinical Research Ed.)|December 1, 2011
Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysisDavid Arnold, Alan Girling, Andrew Stevens, et al.
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
British Journal of Clinical Pharmacology|August 19, 2010
Pharmacoeconomics: NICE's approach to decision-makingMichael Rawlins, David Barnett, Andrew Stevens
International Journal of Technology Assessment in Health Care|September 21, 2006
International diffusion of new health technologies: a ten-country analysis of six health technologiesClaire Packer, Sue Simpson, Andrew Stevens, et al.
International Journal of Technology Assessment in Health Care|September 18, 2012
Analyzing 10 years of early awareness and alert activity in the United kingdomClaire Packer, Matthew Fung, Andrew Stevens
Radiology Case Reports|April 25, 2022
Fatal intracranial hemorrhage as the presenting sign of acute promyelocytic leukemia: A case reportEleanor C Smith, E Andrew Stevens
The Lancet. Oncology|January 1, 2009
Erlotinib for the treatment of non-small-cell lung cancerMeindert Boysen, Carole Longson, Andrew Stevens
BMJ Open|May 8, 2019
Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areasDerek J Ward, Lucy Doos, Andrew Stevens
Journal of Medical Ethics|January 4, 2012
National Institute for Health and Clinical Excellence appraisal and ageismAndrew Stevens, Nick Doyle, Peter Littlejohns, et al.
International Journal of Technology Assessment in Health Care|November 3, 2005
Predicting the impact of new health technologies on average length of stay: development of a prediction frameworkSue Simpson, Claire Packer, Andrew Stevens, et al.
The Lancet. Oncology|April 15, 2008
Rituximab for follicular non-Hodgkin lymphomaElangovan Gajraj, Helen Chung, Carole Longson, et al.
BMJ (Clinical Research Ed.)|December 1, 2011
Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysisDavid Arnold, Alan Girling, Andrew Stevens, et al.
Pageof 9